Kirshner J, Preisler H D, Raza A
Am J Hematol. 1985 Feb;18(2):191-200. doi: 10.1002/ajh.2830180210.
Twenty-three patients with chronic-phase CML have been treated with intermittent courses of busulfan to determine if the duration of unmaintained remission becomes progressively shorter with successive courses of therapy and to determine whether there was a relationship between cluster and colony formation, suicide index of CFUc, labeling index, percentage of cells in S-phase (as determined by cytofluorographic DNA histogram analysis), in vitro sensitivity of the CFUc to busulfan, and response to busulfan therapy. Serial studies in individual patients and the group as a whole revealed no relationship between changes in the cellular parameters described above and response to busulfan. The white blood cell (WBC) doubling time with serial courses of busulfan in individual patients did not always progressively decrease as has been previously reported. In vitro studies of CFUc in chronic-phase CML appear to be of no value in predicting response to busulfan.
23例慢性期慢性粒细胞白血病(CML)患者接受了白消安间歇疗程治疗,以确定未维持缓解期的持续时间是否会随着连续疗程的治疗而逐渐缩短,并确定集落与集落形成、CFUc自杀指数、标记指数、S期细胞百分比(通过细胞荧光DNA直方图分析确定)、CFUc对白消安的体外敏感性以及对白消安治疗的反应之间是否存在关联。对个体患者及整个群体的系列研究表明,上述细胞参数的变化与对白消安的反应之间无关联。个体患者接受连续疗程白消安治疗时,白细胞(WBC)倍增时间并不总是如先前报道的那样逐渐缩短。慢性期CML患者CFUc的体外研究在预测对白消安的反应方面似乎没有价值。